Publications by authors named "Gavin Dunn"

Article Synopsis
  • - Burnout in the medical field is linked to emotional exhaustion, depersonalization, and a decreased sense of achievement, and younger professionals are particularly at risk; this study focused on SNO Young Investigators to better understand their experiences.
  • - An anonymous survey was conducted in 2019 among eligible SNO members, gathering data on their characteristics and using the Maslach Burnout Inventory to assess burnout levels, with analysis including various statistical methods.
  • - The results showed that YI members reported higher levels of emotional exhaustion and depersonalization than the general population, with 30% classified as overextended and 15% experiencing burnout; stress was largely attributed to organizational challenges, indicating a need for systemic interventions.
View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the safety and effectiveness of using disulfiram and copper (DSF/Cu) alongside radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) patients.
  • It involved administering standard RT and TMZ with DSF and Cu, followed by adjuvant treatment, while tracking drug concentrations in the body.
  • Although the maximum tolerated dose of DSF was 375 mg/d, the treatment showed limited overall success, except for promising results in BRAF-mutant patients, suggesting the need for further research.
View Article and Find Full Text PDF

Immunotherapy for glioblastoma (GBM) remains an intensive area of investigation. Given the seismic impact of cancer immunotherapy across a range of malignancies, there is optimism that harnessing the power of immunity will influence GBM as well. However, despite several phase 3 studies, there are still no FDA-approved immunotherapies for GBM.

View Article and Find Full Text PDF

Purpose: Outcomes for patients with glioblastoma (GBM) remain poor despite multimodality treatment with surgery, radiation, and chemotherapy. There are few immunotherapy options due to the lack of tumor immunogenicity. Several clinical trials have reported promising results with cancer vaccines.

View Article and Find Full Text PDF
Article Synopsis
  • Survival rates for glioblastoma IDH wild-type (GBM) vary, emphasizing the need for improved surgical strategies, particularly given that most recurrences occur close to the resection margin.
  • A predictive model was created to determine which GBMs could achieve radiographic gross-total resection (GTR), showing strong accuracy in forecasting surgical outcomes based on tumor characteristics.
  • Analysis of surgical margins using a rapid method revealed that patients with undetected TERT promoter mutations after GTR had significantly better survival rates compared to those with detectable mutations.
View Article and Find Full Text PDF

Unlabelled: Recent clinical trials have highlighted the limited efficacy of T cell-based immunotherapy in patients with glioblastoma (GBM). To better understand the characteristics of tumor-infiltrating lymphocytes (TIL) in GBM, we performed cellular indexing of transcriptomes and epitopes by sequencing and single-cell RNA sequencing with paired V(D)J sequencing, respectively, on TILs from two cohorts of patients totaling 15 patients with high-grade glioma, including GBM or astrocytoma, IDH-mutant, grade 4 (G4A). Analysis of the CD8+ TIL landscape reveals an enrichment of clonally expanded GZMK+ effector T cells in the tumor compared with matched blood, which was validated at the protein level.

View Article and Find Full Text PDF
Article Synopsis
  • Arachnoid cysts are common and usually don't cause problems, but sometimes they can rupture unexpectedly.
  • A 32-year-old person had to have emergency surgery because their cyst broke on its own.
  • It's important to quickly diagnose and treat a ruptured cyst, or it can lead to serious issues like brain swelling.
View Article and Find Full Text PDF

The Arthur and Sandra Irving Cancer Immunology Symposium has been created as a platform for established cancer immunologists to mentor trainees and young investigators as they launch their research career in the field. By sharing their different paths to success, the senior faculty mentors provide an invaluable resource to support the development of the next generation of leaders in the cancer immunology community. This Commentary describes some of the key topics that were discussed during the 2022 symposium: scientific and career trajectory, leadership, mentoring, collaborations, and publishing.

View Article and Find Full Text PDF

About 50% of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) experience recurrences after definitive therapy. The presurgical administration of anti-programmed cell death protein 1 (PD-1) immunotherapy results in substantial pathologic tumor responses (pTR) within the tumor microenvironment (TME). However, the mechanisms underlying the dynamics of antitumor T cells upon neoadjuvant PD-1 blockade remain unresolved, and approaches to increase pathologic responses are lacking.

View Article and Find Full Text PDF

 A low subfrontal dural opening technique that limits brain manipulation was assessed in patients who underwent frontotemporal approaches for anterior fossa lesions.  A retrospective review was performed for cases using a low subfrontal dural opening including characterization of demographics, lesion size and location, neurological and ophthalmological assessments, clinical course, and imaging findings.  A low subfrontal dural opening was performed in 23 patients (17F, 6M), median age of 53 years (range 23-81) with a median follow-up duration of 21.

View Article and Find Full Text PDF

Neoantigens are tumor-specific peptide sequences resulting from sources such as somatic DNA mutations. Upon loading onto major histocompatibility complex (MHC) molecules, they can trigger recognition by T cells. Accurate neoantigen identification is thus critical for both designing cancer vaccines and predicting response to immunotherapies.

View Article and Find Full Text PDF

Many groups have reported lymphatic and glymphatic structures in animal and human brains, but tracer injection into the human brain to demonstrate real-time lymphatic drainage and mapping has not been described. We enrolled patients undergoing standard-of-care resection or stereotactic biopsy for suspected intracranial tumors. Patients received peritumoral injections of Tc-tilmanocept followed by planar or tomographic imaging.

View Article and Find Full Text PDF
Article Synopsis
  • Somatic mutations in non-coding regions and exons can have hidden regulatory effects that are often missed in genetic analysis.
  • RegTools is a free, open-source software that links somatic variants from genomic data to splice junctions, helping identify variants that may lead to abnormal splicing, applied in over 9000 tumor samples.
  • The tool discovered over 235,000 splicing events related to specific junctions, with the ability to analyze variants in key cancer genes like TP53 and CDKN2A, showcasing its effectiveness compared to other analysis methods.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how intrinsic tumor-cell mechanisms, specifically kinases, allow glioblastoma (GBM) cells to evade detection by CD8 T cells, highlighting checkpoint kinase 2 (Chek2) as a key player.
  • An in vivo CRISPR screen identified Chek2 as crucial for tumor cell escape, and its inhibition, along with PD-1 or PD-L1 blockade, improves survival in preclinical glioma models.
  • The research shows that reducing Chek2 enhances antigen presentation and T-cell activation while analysis of human GBMs shows an inverse relationship between Chek2 expression and immune responsiveness, suggesting it as a potential target for improving immune checkpoint therapies in GBM.
View Article and Find Full Text PDF

Background: Adoptive cellular therapies with chimeric antigen receptor T cells have revolutionized the treatment of some malignancies but have shown limited efficacy in solid tumors such as glioblastoma and face a scarcity of safe therapeutic targets. As an alternative, T cell receptor (TCR)-engineered cellular therapy against tumor-specific neoantigens has generated significant excitement, but there exist no preclinical systems to rigorously model this approach in glioblastoma.

Methods: We employed single-cell PCR to isolate a TCR specific for the Imp3 neoantigen (mImp3) previously identified within the murine glioblastoma model GL261.

View Article and Find Full Text PDF

Background: Chimeric antigen receptor (CAR) T cells have achieved remarkable responses in patients with hematological malignancies; however, the potential of this therapeutic platform for solid tumors like glioblastoma (GBM) has been limited, due in large part to the targeting of single antigens in a heterogeneous disease. Strategies that allow CAR T cells to engage multiple antigens concomitantly may broaden therapeutic responses and mitigate the effects of immune escape.

Methods: Here we have developed a novel, dual-specific, tandem CAR T (TanCART) cell with the ability to simultaneously target both EGFRvIII and IL-13Rα2, two well-characterized tumor antigens that are frequently found on the surface of GBM cells but completely absent from normal brain tissues.

View Article and Find Full Text PDF

Background: Mass lesions within the insular are diagnostically and surgically challenging due to the numerous critical cortical, subcortical, and vascular structures surrounding the region. Two main surgical techniques - the transsylvian approach and the transcortical approach - provide access to the insular cortex. Of the range of pathologies encountered, abscesses in the insula are surprisingly rare.

View Article and Find Full Text PDF

Background: Glioblastoma is a fatal disease despite aggressive multimodal therapy. PD-1 blockade, a therapy that reinvigorates hypofunctional exhausted CD8 T cells (T) in many malignancies, has not shown efficacy in glioblastoma. Loss of CD4 T cells can lead to an exhausted CD8 T-cell phenotype, and terminally exhausted CD8 T cells (T ) do not respond to PD-1 blockade.

View Article and Find Full Text PDF

The central nervous system (CNS) antigen-presenting cell (APC) that primes antitumor CD8+ T-cell responses remains undefined. Elsewhere in the body, the conventional dendritic cell 1 (cDC1) performs this role. However, steady-state brain parenchyma cDC1 are extremely rare; cDCs localize to the choroid plexus and dura.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with certain types of brain cancer can be treated using a method called neoadjuvant SRS, which means they get radiation therapy before surgery to help remove the tumors more effectively.
  • A study looked at 24 patients who received this treatment and found that it helped keep their cancer from coming back right after 6 months, although the chances dropped a bit over time.
  • They also reviewed other studies and found that lots of patients who had neoadjuvant SRS before surgery did well, with many showing good control over their cancer within a year after treatment.
View Article and Find Full Text PDF

Throughout human history, advancements in medicine have evolved out of periods of war. The carnage of battlefield injuries provided wartime surgeons an unprecedented opportunity to study anatomy, develop novel techniques, and improve systems of care. As a specialty that was established and evolved during the first half of the 20th century, neurological surgery was heavily influenced by the experiences of its founders during the World Wars I and II.

View Article and Find Full Text PDF